Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21165881 | 0.83 | KDM4E (0.41) | KDM4EHTTALDH1A1CYP2C19 | |
| SCHEMBL25231127 | 0.72 | KDM4E (0.41) | KDM4EHTTALDH1A1NPSR1MEN1 | |
| Hydrochloric Acid SCHEMBL16827936 | 0.71 | MEN1 (0.38) | ALDH1A1MEN1KMT2A | |
| SCHEMBL33526601 | 0.69 | KDM4E (0.36) | KDM4EHTTALDH1A1 | |
| SCHEMBL12802841 | 0.69 | — | — | |
| SCHEMBL17001808 | 0.66 | GAA (0.41) | KDM4EHTTALDH1A1 | |
| SCHEMBL19724045 | 0.66 | HCAR2 (0.43) | KDM4EHTTALDH1A1CYP2C9 | |
| SCHEMBL19723948 | 0.66 | PDE2A (0.37) | KDM4EHTTALDH1A1NPSR1MEN1 | |
| SCHEMBL6467002 | 0.65 | OXTR (0.40) | KDM4EHTTALDH1A1KMT2ACYP2C19 | |
| SCHEMBL6370702 | 0.65 | RAB9A (0.40) | KDM4EHTTMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | KDM4E 1648/4885HTT 1384/4885ALDH1A1 1320/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | KDM4E 1648/4885HTT 1384/4885ALDH1A1 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.